Zentrum für ambulante Hämatologie und Onkologie (ZAHO)
- Address
- Loéstr. 9-11, 53113 Bonn, Germany
Zentrum für ambulante Hämatologie und Onkologie (ZAHO)
The Zentrum für ambulante Hämatologie und Onkologie (ZAHO) is a specialized outpatient center dedicated to hematology and oncology research and treatment. The center demonstrates particular expertise in conducting advanced phase III clinical trials for hematological malignancies, with a strong focus on evaluating novel therapeutic combinations and treatment strategies.
- Multiple myeloma research focusing on newly diagnosed patients
- Evaluation of immunotherapy combinations including isatuximab with standard regimens
- Minimal residual disease (MRD) monitoring and precision oncology approaches
- Comparative studies of induction and maintenance therapy strategies
ZAHO actively participates in complex multi-arm trials investigating progression-free survival outcomes and MRD negativity as key endpoints. Their involvement in large-scale randomized trials, such as the GMMG-HD7 study combining lenalidomide, bortezomib, and dexamethasone with novel immunotherapeutic agents, reflects their commitment to advancing treatment paradigms in hematologic oncology and improving outcomes for patients with plasma cell disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zentrum für ambulante Hämatologie und Onkologie (ZAHO)
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized Trial of Isatuximab Addition to Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | Universitaetsklinikum Heidelberg AöR | Phase III | Not Recruiting | Oct 2018 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 1 | Unknown | 2018-10-18 | 2018-10-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.